Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Contrast Induced Nephropathy - Pipeline Review Report, H2 2017 - Research and Markets

Research and Markets
Posted on: 06 Sep 17

The "Contrast Induced Nephropathy - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Contrast Induced Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Contrast Induced Nephropathy - Overview
  3. Contrast Induced Nephropathy - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Contrast Induced Nephropathy - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Contrast Induced Nephropathy - Companies Involved in Therapeutics Development
  • Pharming Group NV

For more information about this report visit https://www.researchandmarkets.com/research/t432gs/contrast_induced

View source version on businesswire.com: http://www.businesswire.com/news/home/20170906006497/en/

Business Wire
www.businesswire.com

Last updated on: 06/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.